WTO members should start text-based talks on patent waiver proposal: India

A proposal was submitted by 62 co-sponsors -- including India, South Africa, and Indonesia -- seeking patent waivers to manufacture COVID-19-related medical products.

Published: 01st June 2021 03:51 PM  |   Last Updated: 01st June 2021 03:51 PM   |  A+A-

New Director-General of the World Trade Organisation Ngozi Okonjo-Iweala

New Director-General of the World Trade Organisation Ngozi Okonjo-Iweala (Photo | AP)

By PTI

NEW DELHI: The World Trade Organisation (WTO) members must infuse some certainty during this crisis by agreeing to initiate text-based talks on the proposed patent waiver proposal to deal with the COVID-19 pandemic, India has said.

According to India's statement delivered at a TRIPS informal meeting held on May 31, the country has requested to find ways and means to commence text-based negotiations, even if few members continue with their repeated attempts to delay the process.

A proposal was submitted by 62 co-sponsors -- including India, South Africa, and Indonesia -- seeking patent waivers to manufacture COVID-19-related medical products.

In October 2020, India and South Africa had submitted the first proposal, suggesting a waiver on the implementation of certain provisions of the TRIPS Agreement in relation to the prevention, containment or treatment of COVID-19.

The agreement on Trade-Related Aspects of Intellectual Property Rights or TRIPS came into effect in January 1995.

It is a multilateral agreement on intellectual property (IP) rights such as copyright, industrial designs, patents and protection of undisclosed information or trade secrets.

"The virus has not given us a timeout to go on endlessly discussing the need for or benefit of a waiver.

We must rather infuse some certainty in these uncertain times by agreeing to start text-based negotiations on the waiver proposal," India said in the statement.

Not allowing text-based negotiations will do "more harm" to WTO's credibility and this collective failure will be remembered by posterity, according to the statement.

Several rounds of discussions on this proposal have taken place over the past months.

The co-sponsors of the proposal have provided comprehensive responses, including written responses, to many of the concerns and questions raised by the members.

"There is no dearth of arguments, rationale and data provided to exhibit both the waiver's significance and its urgency," it added.

The TRIPS waiver is a necessary, proportionate and temporary legal measure for removing IP barriers and paving the way for more companies to produce COVID-19 vaccines, therapeutics or diagnostics by providing them with the freedom to operate without the fear of infringement of IP rights or the threat of litigation.

"We as cosponsors of the waiver proposal recognise that IPs are not the only barrier to augmenting manufacturing and addressing supply-side constraints.

However, we do believe that IPs are the biggest barrier in addressing supply-side constraints, and thus need to be addressed on priority.

The waiver is not sufficient, but rather a necessary element of a multipronged strategy," the statement said.

 


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.